Table 1. Summary of recent drug studies based on genetic discovery regarding dyslipidemia.

Drug name	Evolocumab25) & alirocumab	Volanesorsen26)	Evinacumab24)
Target gene or protein	PCSK9	APOC3	ANGPTL3
Platform	Humanized monoclonal antibodies	Antisense oligonucleotides	Humanized monoclonal antibody
Stage	Approved worldwide	Approved to treat familial chylomicronemia in some European countries	Approved for HoFH treatment in the United States
Major effects	More than 50% LDL-C reduction on top of statin	Greater than 70% TG reduction	Greater than 50 and 46% LDL-C and TG reductions, respectively, on top of statin & PCSK9 inhibitors
Strengths & limitations	Effective in LDL-C lowering and CV risk reduction; long-term safety not available	First agent for familial chylomicronemia treatment; no outcome studies; Thrombocytopenia	Simultaneous reduction of LDL-C & TG; no outcome studies

CV = cardiovascular; HoFH = homozygous familial hypercholesterolemia; LDL-C = low-density lipoprotein cholesterol; TG = triglycerides.